-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 20, Zejing Pharmaceutical announced that the clinical trial application for ZG005 powder injection has been approved by the FDA for the treatment of patients with solid tumors
ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody powder for injection, which is classified as Class 1
ZG005 has dual-targeted blocking of PD-1 and TIGIT.